Trastuzumab biosimilar - ProBioGen AG/Bio Farma Indonesia
Latest Information Update: 02 Nov 2015
At a glance
- Originator ProBioGen
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action ERBB 2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Breast cancer; Gastric cancer
Most Recent Events
- 28 Oct 2015 Early research in Breast cancer in Germany (Parenteral)
- 28 Oct 2015 Early research in Gastric cancer in Germany (Parenteral)